Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cirrhosis with TIPS for ascit treatment or hydrothorax~* prevention digestive bleeding follow up portal hypertension -~* signed consent~Exclusion Criteria:~* hepatocellular carcinoma out of Milan criteria or palliative phase cancer~* Child Pugh score \> 12~* TIPS indicated for other indication than bellow~* encephalopathy signs : asterixis or confusion~* Hypersensibility to rifaximin, or derivated of rifamycin~* Patients treated by same class antibacterial~* pregnant woman~* Patient with hepatic transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- rifaximin (Type: EXPERIMENTAL): 6 rifaximin caps of 200 mg per day morning and night, during 15 days before TIPS, and after TIPS during 6 months.
- placebo (Type: PLACEBO_COMPARATOR): 6 caps placebo morning and night, 15 days before and 6 months after TIPS

Based on this trial design, predict the completion outcome and termination type (if applicable).